Caxton Associates LP Sage Therapeutics, Inc. Transaction History

Caxton Associates LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $1.19 Million - $1.73 Million	-64,036 Reduced 53.46%	55,745 $1.04 Million
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $884,856 - $1.15 Million	51,746 Added 76.06%	119,781 $2.6 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $1.14 Million - $3.33 Million	68,035 New	68,035 $1.4 Million
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $507,083 - $700,003	18,426 New	18,426 $595,000
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $538,960 - $802,210	-17,550 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $229,401 - $291,610	6,190 Added 54.49%	17,550 $747,000
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $457,353 - $651,723	11,360 New	11,360 $503,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.